Please use this identifier to cite or link to this item:
Title: Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.
Austin Authors: Jo, Helen E;Prasad, Jyotika D;Troy, Lauren K;Mahar, Annabelle;Bleasel, Jane;Ellis, Samantha J;Chambers, Daniel C;Holland, Anne E ;Lake, Fiona R;Keir, Gregory;Goh, Nicole S L ;Wilsher, Margaret;de Boer, Sally;Moodley, Yuben;Grainge, Christopher;Whitford, Helen M;Chapman, Sally A;Reynolds, Paul N;Beatson, David;Jones, Leonie J;Hopkins, Peter;Allan, Heather M;Glaspole, Ian;Corte, Tamera J
Affiliation: Royal Prince Alfred Hospital, Sydney, NSW
Alfred Hospital, Melbourne, VIC
University of Sydney, Sydney, NSW
University of Queensland, Brisbane, QLD
University of Western Australia, Perth, WA
Princess Alexandra Hospital, Brisbane, QLD
Austin Health
Auckland District Health Board, Auckland, NZ
Auckland City Hospital, Auckland, NZ
John Hunter Hospital, Newcastle, NSW
Royal Adelaide Hospital, Adelaide, SA
Auckland, NZ
Queensland Lung Transplant Service, Prince Charles Hospital, Brisbane, QLD
Lung Foundation Australia, Brisbane, QLD
Issue Date: 5-Feb-2018
Publication information: Medical Journal of Australia 2018; 208(2): 82-88
Abstract: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with debilitating symptoms of dyspnoea and cough, resulting in respiratory failure, impaired quality of life and ultimately death. Diagnosing IPF can be challenging, as it often shares many features with other interstitial lung diseases. In this article, we summarise recent joint position statements on the diagnosis and management of IPF from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia, specifically tailored for physicians across Australia and New Zealand. Main suggestions: A comprehensive multidisciplinary team meeting is suggested to establish a prompt and precise IPF diagnosis. Antifibrotic therapies should be considered to slow disease progression. However, enthusiasm should be tempered by the lack of evidence in many IPF subgroups, particularly the broader disease severity spectrum. Non-pharmacological interventions including pulmonary rehabilitation, supplemental oxygen, appropriate treatment of comorbidities and disease-related symptoms remain crucial to optimal management. Despite recent advances, IPF remains a fatal disease and suitable patients should be referred for lung transplantation assessment.
DOI: 10.5694/mja17.00799
ORCID: 0000-0003-2065-4346
Journal: Medical Journal of Australia
PubMed URL: 29385965
Type: Journal Article
Subjects: Lung disease, interstitial
Lung diseases
Lung transplantation
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 18, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.